After six years of continuous data collection, TG Therapeutics Inc. (TGTX) is entering a new phase of refinement. The company's momentum in 2025 is shaped not just by clinical progress, but by a sharpened focus on patient experience and dosing innovation.
With updated long-term results for BRIUMVI and a completed Phase 3 enrollment for a streamlined regimen, TG Therapeutics is laying the groundwork for what could be its next chapter in multiple sclerosis care.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com